Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease

Launched by AFFILIATED HOSPITAL OF NANTONG UNIVERSITY · Jul 8, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness and safety of a medication called liraglutide in helping people who are both obese and have a condition known as Metabolism Associated Fatty Liver Disease (MAFLD). The goal is to see if liraglutide, combined with a healthy diet and exercise, can improve health outcomes for these individuals. Participants will be required to follow a specific diet and exercise plan while taking liraglutide or another medication called orlistat, with the study lasting for 3 months.

To participate in this trial, individuals must be between 65 and 75 years old and have been diagnosed with both obesity and MAFLD. However, people with certain health issues, such as severe liver or kidney problems, or those who are pregnant or breastfeeding, cannot join the study. During the trial, participants can expect to engage in lifestyle changes, including dietary restrictions and regular physical activity, while receiving support and monitoring from the research team. This study aims to provide valuable insights into new treatment options for obesity and MAFLD, which can be crucial for improving overall health.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Clinical diagnosis of Metabolic Associated Fatty Liver Disease(MAFLD);
• • 2. Clinical diagnosis of Obesity.
• Exclusion Criteria:
• • 1. Medicated Hepatitis and Viral Hepatitis;
• • 2. Have severe hepatic or renal insufficiency;
• • 3. have used any weight-loss drug;
• • 4. History of severe gastrointestinal disorders;
• • 5. Malignant tumors, autoimmune diseases, hematologic diseases;
• • 6. Psychopath;
• • 7. Women who are pregnant, breastfeeding or preparing for pregnancy;